{
    "clinical_study": {
        "@rank": "137805", 
        "arm_group": [
            {
                "arm_group_label": "Intravitreal bevacizumab (Avastin)", 
                "arm_group_type": "Active Comparator", 
                "description": "Dosage: 1.25 mg/0.05 ml Frequency: 3 consecutive injections every 4 weeks"
            }, 
            {
                "arm_group_label": "Combined intravitreal fasudil and bevacizumab (Avastin)", 
                "arm_group_type": "Active Comparator", 
                "description": "Dosage: bevacizumab 1.25 mg/0.05 ml +  fasudil 0.025mg/0.05ml Frequency: 3 consecutive injections every 4 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "Eligible eyes are randomized to two groups. Group A will receive three intravitreal\n      injections of bevacizumab at 4 week intervals. In group B, three intravitreal injections of\n      combined bevacizumab and fasudil will be performed with the same frequency.\n\n      Best corrected visual acuity (BCVA) and central macular thickness (CMT) will be evaluated\n      prior to injections and then every 4 weeks for 6 months. Fluorescein angiography will be\n      performed at baseline and at weeks 12 and 24. The two groups will be compared in terms of\n      BCVA and CMT changes."
        }, 
        "brief_title": "Combined Intravitreal Fasudil and Bevacizumab for Diabetic Macular Edema", 
        "condition": "Diabetic Macular Edema", 
        "condition_browse": {
            "mesh_term": [
                "Edema", 
                "Macular Edema"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diabetic patients with diabetic macular edema (DME) and:\n\n          -  Central macula thickness> 250\u03bcm\n\n          -  Visual acuity < 20/40\n\n          -  No active proliferative diabetic retinopathy\n\n          -  No history of intravitreal anti-VEGF drug injection or macular laser photocoagulation\n             (MPC) within the past 3 months\n\n        Exclusion Criteria:\n\n          -  History of vitrectomy\n\n          -  History of cataract surgery within the past 6 months\n\n          -  History of glaucoma or uveitis\n\n          -  Presence of any macular disorder other than DME\n\n          -  Presence of traction on the macula\n\n          -  Significant media opacity\n\n          -  Serum creatinine>3mg/ml"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "74", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01823081", 
            "org_study_id": "91128"
        }, 
        "intervention": [
            {
                "arm_group_label": "Intravitreal bevacizumab (Avastin)", 
                "intervention_name": "Intravitreal injection of bevacizumab (Avastin)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Combined intravitreal fasudil and bevacizumab (Avastin)", 
                "description": "intravitreal injections of bevacizumab and fasudil are performed at two different sites (superior temporal and inferior temporal quadrants respectively)", 
                "intervention_name": "Intravitreal injection of fasudil and bevacizumab (Avastin)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Fasudil", 
                "Bevacizumab"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 28, 2013", 
        "location": {
            "contact": {
                "email": "labbafi@hotmail.com", 
                "last_name": "Hamid Ahmadieh, professor", 
                "phone": "009822591616"
            }, 
            "facility": {
                "address": {
                    "city": "Tehran", 
                    "country": "Iran, Islamic Republic of"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Iran, Islamic Republic of"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "hahmadieh@hotmail.com", 
            "last_name": "Hamid Ahmadieh", 
            "phone": "009822591616"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Iran: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Snellen E-chart", 
                "measure": "Best corrected visual acuity", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "spectral domain optical coherence tomography  (SD OCT)", 
                "measure": "central macular thickness", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01823081"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Shaheed Beheshti Medical University", 
            "investigator_full_name": "Zahra Rabbani Khah", 
            "investigator_title": "Clinical Professor, Ophthalmic Research Center", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Heidelberg fluorescein angiogram (HRA II)", 
                "measure": "Status of macular perfusion", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "clinical examination", 
                "measure": "intraocular inflammation", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }
        ], 
        "source": "Shahid Beheshti Medical University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shahid Beheshti Medical University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2012"
    }
}